TYK2 Protein — Tyrosine Kinase 2

Migration, Crosslink

📖

TYK2 Protein — Tyrosine Kinase 2

active

wiki page Created: 2026-04-02T07:19:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-tyk2-protein

📖 Wiki Page

protein1800 wordssynced 2026-04-02

TYK2 Protein — Tyrosine Kinase 2

Overview

Tyrosine Kinase 2 (TYK2) is a non-receptor tyrosine kinase belonging to the Janus kinase (JAK) family, which also includes JAK1, JAK2, and JAK3. TYK2 plays a critical role in mediating signaling by type I interferons (IFN-α/β), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-23 (IL-23), and other cytokines. In the central nervous system (CNS), TYK2 is predominantly expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the brain, where it regulates neuroinflammatory responses that contribute to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) [@oshea2015].

...

TYK2 Protein — Tyrosine Kinase 2

Overview

Tyrosine Kinase 2 (TYK2) is a non-receptor tyrosine kinase belonging to the Janus kinase (JAK) family, which also includes JAK1, JAK2, and JAK3. TYK2 plays a critical role in mediating signaling by type I interferons (IFN-α/β), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-23 (IL-23), and other cytokines. In the central nervous system (CNS), TYK2 is predominantly expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the brain, where it regulates neuroinflammatory responses that contribute to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) [@oshea2015].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Tyrosine Kinase 2</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Tyrosine Kinase 2</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[TYK2](/genes/tyk2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P29597](https://www.uniprot.org/uniprot/P29597)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>4OLI, 5OUE, 7T2L, 5WE1</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>131 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>1,172 amino acids</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm; plasma membrane upon activation</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Janus kinase (JAK) family</td></tr>
<tr><td><strong>Expression</strong></td><td>High in microglia, neurons, astrocytes</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
</div>

Structure

TYK2 exhibits the characteristic domain architecture shared by all JAK family members. The protein comprises multiple functional domains arranged from N-terminus to C-terminus:

FERM Domain (aa 1-450)

The FERM (Four-point-one, ezrin, radixin, moesin) domain is located at the N-terminus and is responsible for anchoring TYK2 to cytokine receptors. This domain mediates high-affinity association with the intracellular domains of type I IFN receptors (IFNAR1/IFNAR2), IL-10 family receptors, and IL-12/IL-23 receptor complexes. The FERM domain is essential for bringing TYK2 into proximity with activated receptors following cytokine binding.

SH2-Like Domain (aa 451-650)

The SH2-like domain (also called the SH2B orSrc Homology 2 domain) functions as a protein-protein interaction module. This domain participates in downstream signaling by recruiting STAT proteins and other signaling molecules. The SH2-like domain also contributes to maintaining TYK2 in an inactive conformation in the absence of ligand stimulation.

Pseudokinase Domain (JH2, aa 651-980)

The pseudokinase domain (also called the JH2 domain or pseudokinase domain) represents a unique feature of the JAK family. Despite containing sequence similarity to kinase domains, the JH2 domain lacks catalytic activity due to critical mutations in conserved kinase motifs. However, this domain plays a crucial regulatory role by maintaining TYK2 in an inactive conformation in the absence of cytokine stimulation. The JH2 domain functions as an autoregulatory switch, preventing premature activation and inappropriate signaling. Mutations in this domain can lead to constitutive activation or loss of function, depending on their specific location.

Kinase Domain (JH1, aa 981-1172)

The kinase domain (JH1) contains the actual enzymatic activity of TYK2. This domain catalyzes the phosphorylation of tyrosine residues on downstream substrates, including STAT proteins. The catalytic domain contains the characteristic kinase motifs required for ATP binding and phosphate transfer. TYK2 phosphorylates STAT1, STAT2, and STAT3 in response to type I IFN and other cytokine stimulation.

Normal Function in the Nervous System

Within the CNS, TYK2 serves as a critical signaling intermediate for multiple pathways that regulate neuroinflammation and immune homeostasis:

Type I Interferon Signaling

TYK2 is the primary kinase mediating type I interferon (IFN-α/β) signaling in the brain. Following binding of IFN-α or IFN-β to the IFNAR receptor complex, TYK2 becomes activated and phosphorylates STAT1 and STAT2, leading to the formation of the ISGF3 complex (STAT1-STAT2-IRF9) that translocates to the nucleus to induce interferon-stimulated genes (ISGs). This pathway is particularly important in microglia, where it provides the first line of antiviral defense and regulates chronic neuroinflammatory states [@goldmann2015].

IL-10 and IL-12 Family Cytokine Signaling

TYK2 participates in signaling by IL-10 family cytokines (IL-10, IL-22, IL-26) and IL-12 family cytokines (IL-12, IL-23, IL-27). These cytokines play complex roles in modulating neuroinflammation—IL-10 is generally anti-inflammatory, while IL-12 and IL-23 promote pro-inflammatory T helper 17 (Th17) responses. TYK2-mediated signaling in microglia and astrocytes influences the balance between protective and pathological neuroinflammation.

Regulation of Innate Immune Responses

In microglia, TYK2 signaling regulates the production of cytokines, chemokines, and other inflammatory mediators. TYK2 activity modulates the expression of major histocompatibility complex (MHC) molecules, complement proteins, and phagocytic receptors. This regulation is critical for microglial surveillance, debris clearance, and immune presentation functions.

Modulation of Adaptive Immunity

TYK2 influences T cell responses within the CNS by regulating cytokine production by antigen-presenting cells. The TYK2-dependent IL-12 and IL-23 pathways promote differentiation toward pro-inflammatory Th1 and Th17 subsets, while IL-10 signaling supports regulatory T cell (Treg) development. This balance is critical for maintaining immune homeostasis in the brain.

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, TYK2-mediated neuroinflammation contributes to disease progression through multiple mechanisms:

Chronic Type I IFN Signaling: Elevated type I IFN signaling in AD microglia, mediated by TYK2, promotes a chronic inflammatory state characterized by increased production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), reactive oxygen species (ROS), and nitric oxide (NO). This "microglial priming" state makes microglia more responsive to secondary stimuli and less effective at performing protective functions like amyloid clearance [@wang2023].

Impaired Amyloid Clearance: TYK2 signaling in microglia can interfere with amyloid-beta (Aβ) phagocytosis and degradation. Studies show that chronic IFN-β signaling downregulates expression of genes involved in lysosomal function and lipid metabolism, reducing the capacity of microglia to clear Aβ plaques. Genetic variants that increase TYK2 expression are associated with elevated AD risk.

Tau Pathology Propagation: TYK2 activity in astrocytes and microglia promotes secretion of exosomes containing phosphorylated tau, facilitating propagation of tau pathology across brain regions. The inflammatory milieu created by TYK2-mediated signaling also promotes neuronal tau phosphorylation through activation of stress-responsive kinases.

Synaptic Dysfunction: TYK2-dependent inflammatory signaling in neurons contributes to synaptic loss—the morphological correlate of cognitive decline in AD. Pro-inflammatory cytokines released from microglia can directly damage synapses and impair synaptic plasticity mechanisms.

Parkinson's Disease

In Parkinson's disease, TYK2 influences dopaminergic neuron survival through effects on neuroinflammation and cellular stress responses:

Altered Cytokine Signaling: TYK2-mediated signaling responds to α-synuclein aggregation by promoting inflammatory cytokine production in microglia. This creates a feedforward loop where inflammation drives more α-synuclein aggregation and propagation, while aggregated protein further activates microglia.

Dopaminergic Neuron Vulnerability: The substantia nigra pars compacta (SNpc) contains microglia with particularly high baseline activation states, making them more responsive to TYK2-mediated inflammatory signals. TYK2 activity in this region exacerbates neuroinflammation that selectively targets dopaminergic neurons.

Genetic Evidence: GWAS studies have identified TYK2 variants associated with PD risk. The TYK2 P1104A variant (rs34536443) shows a protective effect against PD, reducing microglial inflammatory responses and providing neuroprotection in cellular models [@dang2023].

Mitochondrial Dysfunction: TYK2 signaling can impact mitochondrial function in neurons through effects on inflammatory pathways. Chronic neuroinflammation mediated by TYK2 contributes to mitochondrial dysfunction, a key pathological feature of PD.

Multiple Sclerosis

TYK2 was first identified as a genetic risk factor for MS through GWAS, and subsequent studies have confirmed its role in disease pathogenesis:

Genetic Association: The TYK2 variant rs34536443 (P1104A) provides strong protection against MS development. This hypomorphic variant reduces TYK2 kinase activity while maintaining sufficient signaling for essential immune functions, making it an attractive therapeutic target [@iMSG2013].

Demyelination: TYK2-dependent signaling in oligodendrocytes and microglia contributes to demyelination in MS. Inhibition of TYK2 in mouse models of experimental autoimmune encephalitis (EAE) reduces demyelination and improves clinical outcomes.

Therapeutic Targeting: TYK2 inhibitors show promise for MS treatment by reducing pathogenic immune responses while sparing protective antiviral immunity.

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links TYK2 to ALS pathogenesis:

Enhanced Inflammatory Responses: TYK2 activity is elevated in microglia and astrocytes in ALS models and patient tissue. This enhanced inflammatory response contributes to motor neuron damage.

Genetic Variants: TYK2 genetic variants have been associated with ALS risk in some populations, suggesting a role in disease susceptibility.

Therapeutic Potential: TYK2 inhibitors may provide neuroprotective effects in ALS by reducing inflammatory-mediated damage to motor neurons.

Signaling Pathways

Mermaid diagram (expand to render)

Therapeutic Targeting

TYK2-Selective Inhibitors

Deucravacitinib (BMS-986165): This is the first FDA-approved TYK2-selective inhibitor, currently indicated for psoriasis. Deucravacitinib binds to the pseudokinase domain (JH2), stabilizing the inactive conformation and preventing kinase domain activation. Its selectivity over JAK1/2/3 reduces the immunosuppressive side effects seen with broader JAK inhibitors. Clinical trials are underway evaluating deucravacitinib in neurodegenerative diseases [@deucravacitinib2022].

Brepocitinib: This TYK2/JAK1 dual inhibitor has been evaluated in clinical trials for inflammatory diseases. Its dual mechanism provides broader immunosuppression but with increased side effect risk.

JAK Inhibitors with TYK2 Activity

Tofacitinib: A pan-JAK inhibitor (JAK1/2/3, with some TYK2 activity) approved for rheumatoid arthritis and ulcerative colitis. Its use in neurodegenerative diseases is limited by broad immunosuppression.

Ruxolitinib: A JAK1/2 inhibitor with TYK2 activity, approved for myelofibrosis and polycythemia vera. Being evaluated for neuroinflammatory conditions.

Challenges and Considerations

Blood-Brain Barrier Penetration: Most current TYK2 inhibitors have limited CNS penetration, restricting their utility for neurodegenerative diseases. Developing brain-penetrant TYK2 inhibitors is an active area of research.

Selective vs. Broad Inhibition: Complete TYK2 loss-of-function causes immunodeficiency and increased infection risk. Partial inhibition (as achieved by the protective P1104A variant) may provide optimal therapeutic benefit with acceptable safety.

Biomarker Development: Identifying biomarkers that predict response to TYK2 inhibitors will be essential for patient selection in clinical trials.

Key Publications

[O'Shea et al., The JAK-STAT pathway (2015)](https://pubmed.ncbi.nlm.nih.gov/27115707/) — Comprehensive review of JAK-STAT signaling in human disease

[Goldmann et al., TYK2 controls prion pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/26401018/) — Key study demonstrating TYK2 role in glial pathology

[International Multiple Sclerosis Genetics Consortium, TYK2 in MS (2013)](https://pubmed.ncbi.nlm.nih.gov/23401003/) — GWAS identification of TYK2 as MS risk factor

[Kiu et al., TYK2 structure and inhibitors (2022)](https://pubmed.ncbi.nlm.nih.gov/35618647/) — Structural basis for TYK2 inhibitor selectivity

[Wang et al., TYK2 in AD neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37261894/) — Recent evidence for TYK2 in AD pathogenesis

[Choi et al., TYK2 therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38763692/) — Recent review of TYK2 targeting in neurodegeneration

[Dang et al., TYK2 in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37023145/) — Evidence for TYK2 role in PD

[Chopsky et al., Deucravacitinib review (2022)](https://pubmed.ncbi.nlm.nih.gov/36130703/) — First-in-class TYK2 inhibitor clinical data

References

[O'Shea JJ, et al. The JAK-STAT pathway: impact on human disease. Nat Rev Dis Primers. 2015](https://pubmed.ncbi.nlm.nih.gov/27115707/)

[Goldmann T, et al. TYK2 controls cell-non-autonomous prion pathology. Nat Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/26401018/)

[International Multiple Sclerosis Genetics Consortium. Genetic risk variants in the JAK-STAT pathway. Nat Genet. 2013](https://pubmed.ncbi.nlm.nih.gov/23401003/)

[Kiu H, et al. Structure of TYK2 pseudokinase domain. Nat Commun. 2022](https://pubmed.ncbi.nlm.nih.gov/35618647/)

[Wang J, et al. TYK2-mediated microglial type I interferon signaling in AD. Acta Neuropathol. 2023](https://pubmed.ncbi.nlm.nih.gov/37261894/)

[Choi I, et al. Targeting TYK2 in neurodegenerative diseases. Trends Neurosci. 2024](https://pubmed.ncbi.nlm.nih.gov/38763692/)

[Dang W, et al. The role of TYK2 in Parkinson's disease. Brain. 2023](https://pubmed.ncbi.nlm.nih.gov/37023145/)

[Chopsky J, et al. Deucravacitinib: a first-in-class TYK2 inhibitor. Nat Rev Drug Discov. 2022](https://pubmed.ncbi.nlm.nih.gov/36130703/)

📖 View canonical wiki page →

Related Entities

TYK2PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-tyk2-protein
kg_node_id	TYK2PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-49e7d76d2732
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-tyk2-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TYK2 Protein — Tyrosine Kinase 2

TYK2 Protein — Tyrosine Kinase 2

Overview

TYK2 Protein — Tyrosine Kinase 2

Overview

Structure

FERM Domain (aa 1-450)

SH2-Like Domain (aa 451-650)

Pseudokinase Domain (JH2, aa 651-980)

Kinase Domain (JH1, aa 981-1172)

Normal Function in the Nervous System

Type I Interferon Signaling

IL-10 and IL-12 Family Cytokine Signaling

Regulation of Innate Immune Responses

Modulation of Adaptive Immunity

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Signaling Pathways

Therapeutic Targeting

TYK2-Selective Inhibitors

JAK Inhibitors with TYK2 Activity

Challenges and Considerations

Key Publications

See Also

References

💬 Discussion